Trump has a new plan to help Americans live longer.
Trump Targets Obesity Epidemic With Medicare Reform—But At What Cost?
In a bold move that could reshape the way America tackles obesity, President Donald Trump’s administration is preparing to launch a five-year pilot program that would allow Medicare and Medicaid to cover some of the nation’s most talked-about weight-loss medications.
The initiative—set to begin in April 2026 for Medicaid and January 2027 for Medicare—marks a dramatic policy shift. Previously, weight-loss drugs were not covered by federal programs. But under Trump’s leadership, the administration is reconsidering that stance to better serve the health needs of America’s aging population and reduce long-term health care costs.
America’s Obesity Crisis Gets a Federal Response
At the heart of the plan are GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound—originally developed to treat Type 2 diabetes. These medications have surged in popularity for their ability to curb appetite and help patients lose up to 20% of their body weight, a breakthrough many in the medical community are calling revolutionary.
This proposal builds on a shelved Biden-era plan, but with a distinctly conservative approach. Trump officials say they’re offering flexibility to states and private insurers while ensuring taxpayers aren’t left footing the bill for unproven treatments.
A Conservative Solution to a Costly Crisis
The pilot will operate under the Center for Medicare and Medicaid Innovation, giving states and insurers the choice to opt in. It’s a voluntary system—true to conservative principles—allowing for innovation without heavy-handed federal mandates.
But the question remains: can taxpayers afford it?
GLP-1 drugs come with hefty price tags—Ozempic runs around $936 a month in the U.S., compared to just $169 in Japan. Wegovy costs even more, about $1,349 monthly. According to experts, covering these costs across Medicare and Medicaid could reach tens of billions of dollars.
Dr. Cynthia Cox of the KFF estimates, “It’s a massive financial burden. At $1,000 a month per person, it adds up fast.”
A Delicate Balance Between Health and Fiscal Responsibility
Ethicists and economists are raising red flags. Columbia University’s Dr. Robert Klitzman warns that widespread use could strain the entire health care system. “If two-thirds of Americans took these drugs, it could bankrupt the system,” he told Newsweek.
Still, there’s undeniable momentum behind the push. Many doctors see these medications not just as weight-loss tools but as life-changing treatments that can lower blood sugar, reduce blood pressure, and improve heart health.
Dr. Raj Dasgupta noted, “These medications are helping change the conversation from blaming individuals to treating obesity like the medical condition it truly is.”
Millions Could Be Impacted
With over 100 million Americans classified as obese—and 22 million severely obese—the Trump administration’s plan could affect a huge swath of the population. Currently, only 13 states allow Medicaid to cover GLP-1 drugs for obesity. Medicare, meanwhile, restricts access mostly to patients with diabetes or heart conditions.
The Congressional Budget Office estimates the program could cost Medicare $35 billion over eight years. Despite the cost, proponents argue that long-term savings from reduced hospitalizations and chronic disease treatment could outweigh the immediate expenses.
A Return to Common Sense in Health Care
While critics focus on cost, supporters say this is about offering real solutions to a growing health crisis—without resorting to bloated federal overreach. By making the program optional and built on state flexibility, Trump’s approach could deliver both innovation and accountability.
Novo Nordisk, which manufactures several of the drugs, supports the plan. “Government coverage is essential to making these treatments affordable,” a company spokesperson told The Washington Post.
The plan isn’t finalized yet and may face a public comment period, but it’s clear the Trump administration is positioning itself to take on obesity in a serious—and uniquely conservative—way.